GlycoMimeticsNASDAQ: GLYC

Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors WALTHAM, Mass. , Nov. 12, 2024 /PRNewswire/ -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, announced management will present at the Jefferies London Healthcare Conference on November 19, 2024, at 12:30 pm GMT/7:30 am EDT.

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating GlycoMimetics, Inc. (NASDAQ: GLYC ), relating to a proposed merger with First Crescent Biopharma, Inc. Under the terms of the agreement, the pre-acquisition GlycoMimetics stockholders are expected to own approximately 3.1% of the combined Company and the pre-acquisition Crescent stockholders (inclusive of those investors participating in the pre-closing financing) are expected to own approximately 96.9% of the company.

NEW YORK , Nov. 3, 2024 /PRNewswire/ --  Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating GlycoMimetics, Inc. (NASDAQ: GLYC ), relating to a proposed merger with First Crescent Biopharma, Inc. Under the terms of the agreement, the pre-acquisition GlycoMimetics stockholders are expected to own approximately 3.1% of the combined Company and the pre-acquisition Crescent stockholders (inclusive of those investors participating in the pre-closing financing) are expected to own approximately 96.9% of the company.

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating GlycoMimetics (NASDAQ: GLYC) for possible breaches of fiduciary duty and other violations of law in its transaction with Crescent. Click here to learn how to join our investigation or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. Under the agreement, GlycoMimetics stockholders are expected to own approximately 3.1% of the combined company and Crescent stockholders are expected to own approximately 96.9% o.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of GlycoMimetics, Inc. (NASDAQ: GLYC) and Crescent Biopharma, Inc. is fair to GlycoMimetics shareholders. Upon closing of the proposed transaction, GlycoMimetics stockholders are expected to own approximately 3.1% of the combined company. Halper Sadeh encourages GlycoMimetics shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary.

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the Phase 2 analysis of the adaptive Phase 2/3 study of uproleselan being conducted by the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology in adults with newly diagnosed acute myeloid leukemia (AML) who are 60 years or older and fit for inten.

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it will host a key opinion leader event on Tuesday, June 4, 2024, at 8:30am ET to provide a comprehensive overview of data from the company's pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) acute myeloid leukemia (AML). The event will feature the study'.

GlycoMimetics (GLYC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

GlycoMimetics, Inc. (NASDAQ:GLYC ) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - Chief Executive Officer Edwin Rock - Chief Medical Officer Brian Hahn - Chief Financial Officer Conference Call Participants Roger Song - Jefferies Boris Peaker - TD Cowen Operator Good morning, and thank you for joining the GlycoMimetics Q3 2023 Earnings Call. At this time, all participants are in a listen-only mode.